Overview

  • Product nameAnti-IRF5 antibody - ChIP Grade
    See all IRF5 primary antibodies
  • Description
    Goat polyclonal to IRF5 - ChIP Grade
  • SpecificityThis antibody is expected to recognize all four reported isoforms (NP_002191.1; NP_116032.1; NP_001092097.1; NP_001092099.1).
  • Tested applicationsSuitable for: IHC-P, ChIP, WB, IPmore details
  • Species reactivity
    Reacts with: Dog, Human
    Predicted to work with: Mouse, Rat, Cow
  • Immunogen

    Synthetic peptide: QGPWPMHPAGMQ, corresponding to C terminal amino acids 493-504 of Human IRF5.

  • Positive control
  • General notes

    Principal Names – IRF5; interferon regulatory factor 5 Official Gene Symbol - IRF5 GenBank Accession Number – NP_002191; NP_116032 LocusLink ID - 3663 (human) Gene Ontology terms - RNA polymerase III transcription factor; cell growth and/or maintenance

Properties

Applications

Our Abpromise guarantee covers the use of ab2932 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ChIP Use at an assay dependent dilution. PubMed: 19028697
WB Use a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).Can be blocked with Human IRF5 peptide (ab22939).
IP Use at an assay dependent dilution. PubMed: 19028697

Target

  • Involvement in diseaseGenetic variations in IRF5 are associated with susceptibility to inflammatory bowel disease type 14 (IBD14) [MIM:612245]. IBD14 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
    Genetic variations in IRF5 are associated with susceptibility to systemic lupus erythematosus type 10 (SLEB10) [MIM:612251]. Systemic lupus erythematosus (SLE) is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
    Genetic variations in IRF5 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.
  • Sequence similaritiesBelongs to the IRF family.
    Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Interferon regulatory factor 5 antibody
    • Interferon regulatory factor 5 bone marrow variant antibody
    • IRF 5 antibody
    • IRF-5 antibody
    • Irf5 antibody
    • IRF5_HUMAN antibody
    • SLEB10 antibody
    see all

Anti-IRF5 antibody - ChIP Grade images

  • p53± cells were treated over a time course. The cells were subjected to IP and ChIP analysis using the indicated antibodies and primers. Input is shown in the top four panels; PCR results are shown in the bottom panels. A single panel is shown as representative of amplification from all primer sets after IP with IgG control antibodies for IRF-5.



  • Predicted band size : 58 kDa
    ab2932 staining (2µg/ml) of A549 lysate (RIPA buffer, 30µg total protein per lane).  Primary incubated for 1 hour.  Detected by western blot using chemiluminescence. ab2932 staining (2µg/ml) of A549 lysate (RIPA buffer, 30µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.


  • Predicted band size : 58 kDa

    HEK293 (ab7902) overexpressing human IRF5 and probed with ab2932 at 1µg/ml (mock transfection in lane 2).

  • IHC image of ab2932 staining in human normal cervix (ab29226) formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol B. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab2932, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-IRF5 antibody - ChIP Grade (ab2932)

This product has been referenced in:
  • Li D  et al. Specific detection of interferon regulatory factor 5 (IRF5): A case of antibody inequality. Sci Rep 6:31002 (2016). Read more (PubMed: 27481535) »
  • Massimino M  et al. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis 35:1132-43 (2014). Human . Read more (PubMed: 24445143) »

See all 11 Publications for this product

Product Wall

Application Western blot
Loading amount 30 cells
Gel Running Conditions Reduced Denaturing
Sample Dog Cell lysate - whole cell (CPEK)
Specification CPEK
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Sep 12 2014

Application Western blot
Loading amount 100 µg
Gel Running Conditions Reduced Denaturing (10 % sds)
Sample Human Cell lysate - whole cell (MDM)
Specification MDM
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Abcam user community

Verified customer

Submitted Mar 21 2014

Application Western blot
Loading amount 100 µg
Gel Running Conditions Reduced Denaturing (10)
Sample Mouse Cell lysate - whole cell (BMDM)
Specification BMDM
Treatment 100 nM LPS, 24 h
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Abcam user community

Verified customer

Submitted Mar 20 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (monocyte-derived dendritic cells)
Loading amount 30 µg
Specification monocyte-derived dendritic cells
Gel Running Conditions Reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Jan 17 2013

Thank you very much for your interest in ab2932.

To our knowledge, ab2932 has not been tested in mouse. Therefore, I can offer a discount off a future purchase if you buy ab2932 now, test it in mouse and submit feedback to us in the form of ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"